|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 239/48 | |
| C07D 409/12 | |||
| C07D 403/12 | |||
| C07D 405/12 | |||
| C07D 413/12 | |||
| C07D 417/12 | |||
| A61K 31/505 | |||
| A61P 13/00 |
| (11) | Number of the document | 2343282 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10179618.3 |
| Date of filing the European patent application | 2005-02-25 | |
| (97) | Date of publication of the European application | 2011-07-13 |
| (45) | Date of publication and mention of the grant of the patent | 2015-07-22 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 550499 P | 2004-03-05 | US |
| (72) |
Broka, Chris Allen, US
Carter, David Scott, US
Dillon, Michael Patrick, US
Hawley, Ronald Charles, US
Jahangir, Alam, US
Lin, Clara Jeou Jen, US
Parish, Daniel Warren, US
|
| (73) |
F. Hoffmann-La Roche AG,
Grenzacherstrasse 124, 4070 Basel,
CH
|
| (54) | Diaminopyrimidines as P2X3 and P2X2/3 antagonists |
| Diaminopyrimidines as P2X3 and P2X2/3 antagonists |